<DOC>
	<DOCNO>NCT00234416</DOCNO>
	<brief_summary>The primary objective trial identify dose gemcitabine give 2-hour intravenous ( iv ) infusion administer combination ZD1839 250 mg daily standard course ( 45 Grays [ Gy ] ) radiotherapy patient locally advance , unresectable pancreatic cancer .</brief_summary>
	<brief_title>IRESSA Combined With Radiotherapy &amp; Gemcitabine First-Line Treatment Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirm pancreatic cancer ( aspiration biopsy fine needle [ PAAF ] USE biopsy guide ECOCT ) . It mandatory diagnostic USE recommend aspiration biopsy technique Tumoural volume TAC &lt; 500 cc Aged 18 75 year inclusive Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) Â£ 1 Lifeexpectancy 12 week Women childbearing potential must willing practice reliable method birth control prevent pregnancy Previous radiotherapy chemotherapy malignant disease Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ In opinion investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease ) Absolute neutrophil count ( ANC ) less 1.5 x 109/litre ( L ) , platelets less 100 x 109/L haemoglobin less 9 mg/dL ; Prothrombin time ( PT ) less 50 % ; Serum bilirubin great 2.5 time upper limit reference range ( ULRR ; Creatinine clearance le 45 mL/min ; ALT AST great 2.5 time ULRR Active dermatosis ( e.g . psoriasis , eczema ) Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , drug know corneal toxicity Known , severe hypersensitivity ZD1839 excipients product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>EGF-R</keyword>
</DOC>